The Centers for Disease Control and Prevention (CDC) has selected Hager Sharp to help promote adolescent immunizations with a particular emphasis on HPV (human papillomavirus) vaccination. The two-year, $7.9 million contract includes formative research, message development, partnership development and outreach, media planning and placement, and evaluation of the effort.
“With one in four people infected with at least one strain of HPV, this is a critically important public health issue,” said Hager Sharp CEO Lynne Doner Lotenberg. “We are eager to support CDC in educating providers and parents about HPV vaccination. We anticipate that our unique mix of HPV knowledge, social marketing principles, and strategic planning will help CDC in this effort.”
Hager Sharp Vice President Katherine Nicol will lead the work, with support from Atlanta-based Vice President Shelly Spoeth and Senior Vice President of Strategic Planning and Research Christina Nicols. For the past few years, Nicol has led Hager Sharp’s efforts on behalf of the President’s Cancer Panel, including its series on HPV that culminated in the 2014 release of the report, Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer.
The CDC estimates that increasing HPV vaccination rates from current levels to 80 percent would prevent an additional 53,000 future cervical cancer cases in the U.S. among girls age 12 or younger over the course of their lifetimes. Thousands of cases of other HPV-associated cancers in the U.S.—a growing proportion of which will occur in males—would also likely be prevented within the same timeframe.
Source: Hager Sharp News